Merck Seeks Narrowed Arcoxia Indication In Response To “Approvable” Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Company expects to hear from FDA in April on 30 mg and 60 mg once-daily doses of the Vioxx follow-on drug.
You may also be interested in...
FDA Cold-Cox Merck; Arcoxia “Not Approvable” For Osteoarthritis
Agency indicates more data is needed on benefit-to-risk profile of the COX-2 inhibitor, but Merck is mum on whether it will continue to pursue approval.
FDA Cold-Cox Merck; Arcoxia “Not Approvable” For Osteoarthritis
Agency indicates more data is needed on benefit-to-risk profile of the COX-2 inhibitor, but Merck is mum on whether it will continue to pursue approval.
Arcoxia GI Benefit Does Not Outweigh CV Risk, Committee Says
FDA’s Arthritis Drugs Advisory Committee votes 20-1 against recommending approval of Merck’s Vioxx follow-on etoricoxib.